Decoy explores pan-filovirus program via FDA Animal Rule after 1.56 μM result
AI Summary- Decoy Therapeutics announced exploration of a pan-filovirus D-MAV program through the FDA Animal Rule.
- 1.56 μM was the candidate's IC50 against wild-type Ebola Zaire in cell-based assays.
- Decoy said it is pursuing grants and partnerships to support preclinical and clinical development.